Research Study Investigating How Well NDec Works in People With Sickle Cell Disease
Status:
Not yet recruiting
Trial end date:
2024-03-29
Target enrollment:
Participant gender:
Summary
This study will look at how well a potentially new medicine called NDec works and is
tolerated in people with sickle cell disease. NDec is a combination of two medicines
(decitabine-tetrahydrouridine). Both medicines are new for the treatment of sickle cell
disease,
Participants will either get NDec, placebo or continue on Hydroxyurea (HU) - which treatment
participants get is decided by chance. If participants get NDec or the placebo, they will get
capsules to take twice weekly.
The study will last for about a year.